Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026
Autonomix Medical will present new long-term clinical data regarding its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma at ECIO 2026. The presentation aims to showcase long-term outcomes from this minimally invasive technique, which targets nerves via the vascular system to provide lasting pain relief for patients suffering from severe pain associated with pancreatic cancer.
THE WOODLANDS, TX, April 22, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that new long-term clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the European Conference on Interventional Oncology (ECIO) 2026 being held April 26 – 30, 2026 in Basel CH.